Great Debate: Is the New Risk Factor-Weighted Clinical Likelihood Model Useful for Estimating Pre-Test Probability of Obstructive Coronary Artery Disease?
Posted inCardiology news

Great Debate: Is the New Risk Factor-Weighted Clinical Likelihood Model Useful for Estimating Pre-Test Probability of Obstructive Coronary Artery Disease?

The RF-CL model is a new ESC-recommended tool for estimating the pre-test probability of obstructive CAD in suspected chronic coronary syndromes. It improves risk stratification and may reduce unnecessary testing, though symptom interpretation and practical limits remain debated.
Precision Phenotyping in Cardiometabolic Medicine: Genetic Susceptibility of Diabetes Subtypes and Coronary Artery Disease Risk
Posted inCardiology Clinical Updates Diabetes & Endocrinology news

Precision Phenotyping in Cardiometabolic Medicine: Genetic Susceptibility of Diabetes Subtypes and Coronary Artery Disease Risk

This review synthesizes evidence on the genetic architecture of adult-onset diabetes subtypes, highlighting that Moderate Obesity-related Diabetes (MOD) is uniquely and causally linked to coronary artery disease risk through polygenic and Mendelian randomization analyses.
Global Variations in Patient Radiation Exposure for Coronary Artery Disease Diagnosis: A Synthesized Review of the INCAPS 4 Findings
Posted inCardiology Clinical Updates news Radiology

Global Variations in Patient Radiation Exposure for Coronary Artery Disease Diagnosis: A Synthesized Review of the INCAPS 4 Findings

This review analyzes global radiation doses in CAD diagnostic imaging based on the INCAPS 4 study. It highlights significant disparities across modalities and regions, revealing that patients in low-income countries and those undergoing CCTA face substantially higher radiation risks, necessitating urgent standardized protocols.
Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial
Posted inCardiology Diabetes & Endocrinology news

Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial

The ABILITY Diabetes Global trial demonstrates that the Abluminus DES+ sirolimus-eluting stent failed to meet non-inferiority compared to the XIENCE everolimus-eluting stent in patients with diabetes, showing significantly higher rates of target-lesion failure and revascularization at 12 months.